Adrenal Insufficiency Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Adrenal Insufficiency Market is projected to expand from USD 412.09 Million in 2025 to USD 701.45 Million by 2031, achieving a compound annual growth rate (CAGR) of 9.27%. This market encompasses diagnostic tests and therapeutic agents developed for conditions where the adrenal glands fail to synthesize adequate steroid hormones. Market growth is primarily fueled by the increasing prevalence of secondary adrenal insufficiency associated with prolonged glucocorticoid treatment for chronic inflammatory disorders. Furthermore, heightened clinician awareness and refined screening protocols are boosting diagnosis rates, thereby enlarging the patient demographic in need of hormone replacement therapy.

Despite this growth, the market encounters substantial obstacles related to preventing acute, life-threatening complications. The risk of fatal adrenal crises resulting from delayed treatment acts as a significant impediment to optimal patient care and market confidence. Data from the European Society of Endocrinology indicates that in 2025, the incidence of overt adrenal crisis was 4.4 cases per 100 person-years. This statistic underscores the enduring challenge of managing the condition effectively and highlights the urgent requirement for superior emergency therapeutic interventions.

Market Drivers

The advancement of Research and Development and the broadening of therapeutic product pipelines are fundamentally transforming the market, specifically through the introduction of non-glucocorticoid treatments for conditions such as Congenital Adrenal Hyperplasia. Pharmaceutical companies are actively pursuing corticotropin-releasing factor type 1 (CRF1) receptor antagonists to alleviate the severe side effects linked to chronic high-dose steroid regimens.

This clinical progress is illustrated by Crinetics Pharmaceuticals; as reported by BioSpace in January 2026, Phase 2 trial findings revealed that 88% of patients utilizing the investigational drug atumelnant reached physiologic glucocorticoid dosage levels. These developments indicate a strong commercial future for the industry, further emphasized by the rapid adoption of recently approved treatments. For example, BioSpace noted in January 2026 that Neurocrine Biosciences’ newly approved drug Crenessity generated $165.3 million in revenue during the first three quarters of 2025, demonstrating substantial demand for effective treatments.

Furthermore, technological breakthroughs in drug delivery systems are propelling market growth by meeting the crucial demand for precise, age-specific dosing. The launch of modified-release capsules and multiparticulate granules has markedly enhanced treatment adherence, especially among pediatric patients who have traditionally faced difficulties with fractionated adult tablets.

These advancements in delivery methods are yielding strong financial results for manufacturers specializing in niche adrenal insufficiency products. In February 2025, Eton Pharmaceuticals reported record quarterly product revenue of $11.6 million for the fourth quarter of 2024, a surge largely credited to the commercial success of its pediatric-specific hydrocortisone granules. These innovations ensure the patient population obtains consistent hormone replacement, thereby enhancing disease management and lowering the risk of acute complications.

Market Challenges

The central obstacle inhibiting the Global Adrenal Insufficiency Market is the enduring struggle to prevent acute and life-threatening complications, specifically adrenal crises. This safety barrier substantially erodes market confidence, as the inability to assure patient stability discourages the broad implementation of standard therapeutic protocols. The intricacy involved in adjusting hormone dosages to avert fatal episodes triggered by sudden physiological stress establishes a high-risk scenario that limits the growth of the treated patient population. Consequently, clinicians frequently exhibit reluctance to aggressively treat borderline cases because of the serious liability and health consequences linked to potential treatment failure, which in turn slows market momentum.

This challenge is exacerbated by the sheer magnitude of the population that requires precise safety monitoring to avert such complications. The logistical strain of preventing emergencies across such a vast group constrains the effectiveness of existing care delivery models. According to the Endocrine Society, in 2024, at least 1% of the general population was using chronic glucocorticoid therapy, a demographic recognized as being at perpetual risk for adrenal suppression and related emergencies. This statistic demonstrates the extent of the difficulty; the market faces a struggle to maintain consistent safety standards across this extensive patient base, which directly hinders the scalability of treatment solutions.

Market Trends

The creation of pre-filled autoinjectors for emergency crisis rescue is dramatically reshaping the safety landscape by meeting the urgent requirement for rapid intervention during adrenal crises. Existing emergency protocols frequently depend on complicated vial-and-syringe reconstitution kits, which are susceptible to user error and delays during high-stress situations. The introduction of pre-filled or needle-free auto-injector devices simplifies this procedure into a single, intuitive step, guaranteeing immediate hydrocortisone administration and lowering the probability of fatal results. This innovation constitutes a significant commercial sector; according to a March 2025 press release from Crossject, their strategic collaboration to commercialize the Zeneo hydrocortisone autoinjector addresses a market opportunity estimated to surpass $200 million in the United States alone.

Additionally, the growth of pediatric-specific oral liquid formulations is effectively bridging the gap in precise dose titration that solid oral dosage forms cannot resolve. Although recent granule-based therapies have enhanced adherence, liquid solutions provide superior flexibility, enabling clinicians to infinitely modify hormone replacement dosages to align with a child’s rapid growth velocity and changing body surface area. This transition toward highly titratable liquid options is fueling strong financial optimism within the industry. As noted by Eton Pharmaceuticals in their "Second Quarter 2025 Financial Results" in August 2025, the company projected an annual revenue run rate of $80 million for the third quarter, a forecast bolstered by the addition of Khindivi, the first FDA-approved oral liquid hydrocortisone, to their portfolio.

Key Players Profiled in the Adrenal Insufficiency Market

• Acrotech Biopharma, Inc.
• Bausch Health, Canada Inc.
• AdvaCare International Limited
• Weefsel Pharma
• Cipla Inc.
• Pfizer Inc.
• Wellona Pharma
• Eugia US LLC
• Sandoz Inc.
• Prevego Healthcare & Research Pvt Ltd.

Report Scope

In this report, the Global Adrenal Insufficiency Market has been segmented into the following categories:

Adrenal Insufficiency Market, by Type:

• Primary
• Secondary
• Tertiary

Adrenal Insufficiency Market, by Treatment:

• Glucocorticoid
• Corticotropin
• Others

Adrenal Insufficiency Market, by Route of Administration:

• Oral
• Injectables
• Others

Adrenal Insufficiency Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Adrenal Insufficiency Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adrenal Insufficiency Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.